Literature DB >> 21536911

Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes.

Janine M Lamonica1, Wulan Deng, Stephan Kadauke, Amy E Campbell, Roland Gamsjaeger, Hongxin Wang, Yong Cheng, Andrew N Billin, Ross C Hardison, Joel P Mackay, Gerd A Blobel.   

Abstract

Acetylation of histones triggers association with bromodomain-containing proteins that regulate diverse chromatin-related processes. Although acetylation of transcription factors has been appreciated for some time, the mechanistic consequences are less well understood. The hematopoietic transcription factor GATA1 is acetylated at conserved lysines that are required for its stable association with chromatin. We show that the BET family protein Brd3 binds via its first bromodomain (BD1) to GATA1 in an acetylation-dependent manner in vitro and in vivo. Mutation of a single residue in BD1 that is involved in acetyl-lysine binding abrogated recruitment of Brd3 by GATA1, demonstrating that acetylation of GATA1 is essential for Brd3 association with chromatin. Notably, Brd3 is recruited by GATA1 to both active and repressed target genes in a fashion seemingly independent of histone acetylation. Anti-Brd3 ChIP followed by massively parallel sequencing in GATA1-deficient erythroid precursor cells and those that are GATA1 replete revealed that GATA1 is a major determinant of Brd3 recruitment to genomic targets within chromatin. A pharmacologic compound that occupies the acetyl-lysine binding pockets of Brd3 bromodomains disrupts the Brd3-GATA1 interaction, diminishes the chromatin occupancy of both proteins, and inhibits erythroid maturation. Together these findings provide a mechanism for GATA1 acetylation and suggest that Brd3 "reads" acetyl marks on nuclear factors to promote their stable association with chromatin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536911      PMCID: PMC3107332          DOI: 10.1073/pnas.1102140108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  Global regulation of erythroid gene expression by transcription factor GATA-1.

Authors:  John J Welch; Jason A Watts; Christopher R Vakoc; Yu Yao; Hao Wang; Ross C Hardison; Gerd A Blobel; Lewis A Chodosh; Mitchell J Weiss
Journal:  Blood       Date:  2004-08-05       Impact factor: 22.113

2.  CREB-Binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites.

Authors:  H L Hung; J Lau; A Y Kim; M J Weiss; G A Blobel
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  GATA-1 is required for expression of Fc{epsilon}RI on mast cells: analysis of mast cells derived from GATA-1 knockdown mouse bone marrow.

Authors:  Chiharu Nishiyama; Tomonobu Ito; Makoto Nishiyama; Shigehiro Masaki; Keiko Maeda; Nobuhiro Nakano; William Ng; Kanako Fukuyama; Masayuki Yamamoto; Ko Okumura; Hideoki Ogawa
Journal:  Int Immunol       Date:  2005-06-20       Impact factor: 4.823

4.  Regulation of activity of the transcription factor GATA-1 by acetylation.

Authors:  J Boyes; P Byfield; Y Nakatani; V Ogryzko
Journal:  Nature       Date:  1998-12-10       Impact factor: 49.962

Review 5.  Mitotic repression of the transcriptional machinery.

Authors:  J M Gottesfeld; D J Forbes
Journal:  Trends Biochem Sci       Date:  1997-06       Impact factor: 13.807

6.  Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line.

Authors:  M J Weiss; C Yu; S H Orkin
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

7.  Differentially expressed genes in endothelial differentiation.

Authors:  Hideshi Ishii; Koshi Mimori; Masaki Mori; Andrea Vecchione
Journal:  DNA Cell Biol       Date:  2005-07       Impact factor: 3.311

8.  CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation.

Authors:  G A Blobel; T Nakajima; R Eckner; M Montminy; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

9.  Structure and ligand of a histone acetyltransferase bromodomain.

Authors:  C Dhalluin; J E Carlson; L Zeng; C He; A K Aggarwal; M M Zhou
Journal:  Nature       Date:  1999-06-03       Impact factor: 49.962

10.  A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development.

Authors:  R A Shivdasani; Y Fujiwara; M A McDevitt; S H Orkin
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

View more
  100 in total

Review 1.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

Review 2.  Transcriptional mechanisms underlying hemoglobin synthesis.

Authors:  Koichi R Katsumura; Andrew W DeVilbiss; Nathaniel J Pope; Kirby D Johnson; Emery H Bresnick
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

3.  RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.

Authors:  Sarah Picaud; Christopher Wells; Ildiko Felletar; Deborah Brotherton; Sarah Martin; Pavel Savitsky; Beatriz Diez-Dacal; Martin Philpott; Chas Bountra; Hannah Lingard; Oleg Fedorov; Susanne Müller; Paul E Brennan; Stefan Knapp; Panagis Filippakopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

4.  Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression.

Authors:  Mar Gacias; Guillermo Gerona-Navarro; Alexander N Plotnikov; Guangtao Zhang; Lei Zeng; Jasbir Kaur; Gregory Moy; Elena Rusinova; Yoel Rodriguez; Bridget Matikainen; Adam Vincek; Jennifer Joshua; Patrizia Casaccia; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2014-06-19

5.  Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3.

Authors:  Roland Gamsjaeger; Sarah R Webb; Janine M Lamonica; Andrew Billin; Gerd A Blobel; Joel P Mackay
Journal:  Mol Cell Biol       Date:  2011-05-09       Impact factor: 4.272

Review 6.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

7.  Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.

Authors:  Gillian A Horne; Helen J S Stewart; Jacqueline Dickson; Stefan Knapp; Bernard Ramsahoye; Timothy Chevassut
Journal:  Stem Cells Dev       Date:  2014-12-17       Impact factor: 3.272

8.  Characterization of BRD4 during mammalian postmeiotic sperm development.

Authors:  Jessica M Bryant; Greg Donahue; Xiaoshi Wang; Mirella Meyer-Ficca; Lacey J Luense; Angela H Weller; Marisa S Bartolomei; Gerd A Blobel; Ralph G Meyer; Benjamin A Garcia; Shelley L Berger
Journal:  Mol Cell Biol       Date:  2015-02-17       Impact factor: 4.272

9.  Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

Authors:  Pan Tang; Jifa Zhang; Jie Liu; Cheng-Ming Chiang; Liang Ouyang
Journal:  J Med Chem       Date:  2021-02-22       Impact factor: 7.446

10.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

Authors:  Christopher J Ott; Nadja Kopp; Liat Bird; Ronald M Paranal; Jun Qi; Teresa Bowman; Scott J Rodig; Andrew L Kung; James E Bradner; David M Weinstock
Journal:  Blood       Date:  2012-08-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.